Outcomes of second line chemotherapy (II-LC) in platinum resistant non small cell lung cancer (NSCLC)

Tassinari, Davide; Santelmo, Carlotta; Tamburini, Emiliano; Possenti, C.; Agli, Luigi Lazzari

doi:10.1200/jco.2008.26.15_suppl.19058

Search citation statements

Order By: Relevance

Paper Sections

Select...

-A Reference Regimen1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2008

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No major QoL diff erences were noted. Th e second meta-analysis compared docetaxel with any other CX agent (pemetrexed, vinorelbine, topotecan) [30]. No signifi cant diff erences between treatments were noted in 1 year survival rate (OR = 0.85), RR (OR = 0.80) or TTP (OR = 0.82).…”

Section: -A Reference Regimenmentioning

confidence: 98%

Non-small cell lung cancer

Dediu

Hilbe

2008

memo

View full text Add to dashboard Cite

Non-small cell lung cancer 4/2008 ASCO Update -NSCLC 247 Th is congress report gives an overview of the most important news concerning lung cancer presented at ASCO 2008 meeting. Th e most interesting highlights were: (1) For the 1st-line treatment of patients with advanced NSCLC, Cetuximab, added to a platinum-based chemotherapy, sets a new standard and side eff ects (like acne-like rash) were as expected and manageable. (2) Insulin-like growth factor type I receptor (IGF-IR) in combination with chemotherapy could be an optimistic therapeutic option for NSCLC with squamous cell histology since fi rst results proved a response rate of 72% in this histological subtype. (3) Erlotinib as 1st-line treatment for elderly patients showed encouraging effi cacy. (4) For patients without progression after the fi rst line regimen, early introduction of a second line agent is an effi cient novel therapeutic option. Further validating studies are warranted.

show abstract

Section: -A Reference Regimenmentioning

confidence: 98%